BLI Banque de Luxembourg Investments Sells 7,700 Shares of Eli Lilly and Company $LLY

BLI Banque de Luxembourg Investments cut its holdings in Eli Lilly and Company (NYSE:LLY) by 30.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 17,500 shares of the company’s stock after selling 7,700 shares during the period. BLI Banque de Luxembourg Investments’ holdings in Eli Lilly and Company were worth $18,905,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after acquiring an additional 1,006,885 shares during the last quarter. State Street Corp increased its position in Eli Lilly and Company by 0.6% during the third quarter. State Street Corp now owns 34,726,558 shares of the company’s stock valued at $26,496,364,000 after acquiring an additional 219,590 shares during the last quarter. Capital Research Global Investors increased its position in Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after acquiring an additional 4,332,008 shares during the last quarter. Capital World Investors increased its position in Eli Lilly and Company by 0.4% during the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after acquiring an additional 61,851 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in Eli Lilly and Company by 4.1% during the third quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock valued at $11,112,164,000 after acquiring an additional 574,229 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Up 1.6%

LLY opened at $1,149.38 on Tuesday. The firm has a 50-day simple moving average of $979.60 and a two-hundred day simple moving average of $1,013.80. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,182.73. The company has a market capitalization of $1.08 trillion, a PE ratio of 40.83, a price-to-earnings-growth ratio of 1.24 and a beta of 0.53. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the firm earned $3.34 EPS. The business’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Late-stage data for retatrutide showed strong weight-loss results and benefits for obesity-linked conditions, helping convince investors that Lilly can extend its lead in the fast-growing GLP-1 market. Reuters: Lilly shares jump as analysts see retatrutide data extending obesity market edge
• Positive Sentiment: Lilly also reported encouraging Phase 3 results for Foundayo (orforglipron), its oral GLP-1 drug, including better A1C control and weight loss than oral semaglutide in a head-to-head study, with FDA submission planned by the end of the second quarter. PR Newswire: Lilly’s oral GLP-1 Foundayo delivered superior A1C control and weight loss
• Positive Sentiment: Additional ADA conference updates showed Foundayo produced meaningful weight loss in women across menopause stages, broadening the potential patient population and supporting the drug’s commercial opportunity. PR Newswire: Foundayo associated with significant weight loss in women at every stage of menopause
• Positive Sentiment: Peer weakness also appears to be helping Lilly: Zealand Pharma’s disappointing GLP-1 data and a selloff in competing obesity names highlighted Lilly’s relative advantage in the weight-loss race. The Motley Fool: A Weight-Loss Rival Just Crashed 23%
• Neutral Sentiment: Lilly’s 340B deadline passed and hospitals are now evaluating the implications; this looks more like a policy/pricing issue than an immediate earnings catalyst. Becker’s Hospital Review: Eli Lilly’s 340B deadline passes
• Neutral Sentiment: Reports that Medicare’s GLP-1 bridge program may test Lilly’s obesity strategy add some uncertainty, but the impact is still unclear. MSN: Eli Lilly faces new test with Medicare GLP-1 Bridge program
• Neutral Sentiment: Lilly also completed a bioavailability study for early-stage asset LY4064809, which is a pipeline update but not likely a near-term stock driver. TipRanks: Lilly advances early-stage asset with completion of LY4064809 bioavailability study

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Barclays upped their price objective on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Monday, May 4th. Morgan Stanley restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Friday. Jefferies Financial Group upped their price objective on Eli Lilly and Company from $1,300.00 to $1,330.00 in a research note on Thursday, May 21st. CICC Research upped their price objective on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 11th. Finally, UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $1,227.00.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.